Table 1.

Case reports of antihormonal therapy for breast cancer with leptomeningeal disease

Age, years	DFI	Prior therapy	Treatment for LC	PFS	Reference
72	7 years	FAC×6, tamoxifen×5 years, progestin, aminoglutethimide	Formestane	>2 years	5
66	0	Prednisone	Letrozole	>1 year	6
32	1 year	CMF	Ovarian ablation/tamoxifen	10 months	7
52	9 years	CMF×6	Tamoxifen, local RT	6 months	7
41	33 months	CMF×6, tamoxifen, for LC whole brain RT, ITMx, cisplatin–etoposide	Letrozole	16 months	8
34	10 years	CMF, tamoxifen, paclitaxel/trastuzumab docetaxel/epirubicin, ITMx with etoposide	Exemestane	10 months	9
60	5 years	CMF, tamoxifen×5 years ITMx	Letrozole	>36 months	10
47	0	None	Tamoxifen/ovarian ablation, letrozole, everolimus	10 months	11

CMF, cyclophosphamide, methotrexate, 5-FU; DFI, disease-free interval; FAC, 5FU, adriamycin, cyclophosphamide; ITMx, intrathecal methotrexate; LC, leptomeningeal carcinomatosis; PFS, progression-free survival; RT, radiotherapy.